| 赖河青.雷公藤红素联合顺铂对舌鳞状细胞癌作用机制的研究[J].浙江中西医结合杂志,2017,27(6): |
| 雷公藤红素联合顺铂对舌鳞状细胞癌作用机制的研究 |
| Investigation about action mechanism of oral squamous cell carcinoma affected by combination of tripterine and cisplatin |
| 投稿时间：2016-12-16 修订日期：2017-04-13 |
| DOI： |
| 中文关键词: 雷公藤红素 顺铂 Tca8113 |
| 英文关键词:Tripterine cisplatin Tca8113 |
| 基金项目: |
|
| 摘要点击次数: 1153 |
| 全文下载次数: 3 |
| 中文摘要: |
| 【】：目的：探讨雷公藤红素联合顺铂对舌鳞状细胞癌(Tca8113细胞)的作用机制。方法：将Tca8113细胞分为：对照组(0μmol/L顺铂和0μg/mL雷公藤红素)、顺铂组(15μmol/L顺铂)、雷公藤红素组(50μg/mL雷公藤红素)以及联合组(15μmol/L顺铂和50μg/mL雷公藤红素),MTT法检测细胞活力, 酶联免疫吸附法测定血管内皮生长因子(VEGF)、血管内皮生长因子-C(VEGF-C)、Bcl-2(抗凋亡蛋白)、Bax(凋亡蛋白)水平。结果：顺铂组、雷公藤红素中Tca8113细胞的存活率低于对照组,差异有统计学意义(P <0.05),联合组的存活率低于对照组、顺铂组与雷公藤红素组,差异有统计学意义(P <0.05),雷公藤红素组的存活率低于顺铂组,但差异无统计学意义(P >0.05)；顺铂组、雷公藤红素组Tca8113细胞的VEGF、VEGF-C、Bcl-2的水平低于对照组,Bax的水平高于对照组,差异有统计学意义(P <0.05)；联合组的VEGF、VEGF-C、Bcl-2低于对照组、顺铂组与雷公藤红素组,Bax高于对照组、顺铂组与雷公藤红素组,差异有统计学意义(P <0.05)；雷公藤红素组的VEGF、VEGF-C、Bcl-2、Bax水平与顺铂组相近,差异无统计学意义(P >0.05)。结论：雷公藤红素联合顺铂治疗舌鳞状细胞癌疗效优于顺铂和雷公藤红素单独治疗,作用机制可能与其抑制VEGF、VEGF-C、Bcl-2的表达,促进Bax的表达相关。 |
| 英文摘要: |
| SObjective：To investigate mechanism of action for oral squamous cell carcinoma affected by combination of tripterine and cisplatin. Method: Divide Tca8113 cell into four groups: control group( 0μmol/L cisplatin and 0μg/mL tripterine), cisplatin group (15μmol/L cisplatin, tripterine group(50μg/mL tripterine) and combined group(15μmol/L cisplatin and50μg/mL tripterine). Using the MTT assay to assess cell activity. Then using ELISA Assay to detect the level of VEGF, VEGF-C, Bcl-2 and Bax. Results: In cisplatin group and tripterine group, cell viability of Tca8113 cell was lower than that of the control group, and the difference has statistical significance (P<0.05). The cell viability for the combined group was lower than that for the control group, cisplatin group and tripterine group, and the difference has statistical significance(P<0.05). The cell viability of tripterine group was lower than that of the cisplatin group , but the difference was not statistically significant(P>0.05). Tca8113 cell"s VEGF, VEGF-C and Bcl-2 levels in cisplatin group and tripterine group were lower than the control group, but their Bax level was higher than the control group, and difference was statistically significant(P<0.05). The combined group"s VEGF, VEGF-C and Bcl-2 levels were lower than the control group, cisplatin group and tripterine group,but its Bax level was higher than those three groups, and difference was statistically significant.(P<0.05). Tripterine group"s VEGF, VEGF-C, Bcl-2 and Bax levels were very similar to cisplatin group, and difference has no statistical significance(P>0.05). Conclusion: The combination of tripterine and cisplatin cures oral squamous cell carcinoma better than using these two separately. Mechanism of action may inhibit the expression of VEGF, VEGF-C and Bcl-2, but promote expression of Bax. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
